Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: The mutations and salvage study

被引:12
作者
Gianotti, N
Mondino, V
Rossi, MC
Chiesa, E
Mezzaroma, I
Ladisa, N
Guaraldi, G
Torti, C
Tarquini, P
Castelli, P
Di Carlo, A
Boeri, E
Keulen, W
Mc Kenna, P
Lazzarin, A
机构
[1] Univ Vita Salute San Raffaele, Clin Malattie Infett, Milan, Italy
[2] Osped L Sacco, Clin Malattie Infett, Milan, Italy
[3] Diagnost & Ric San Raffaele, Milan, Italy
[4] Osped Riuniti Pallanza, Div Malattie Infett, Verbania, Italy
[5] Osped Ca Foncello, Div Malattie Infett, Treviso, Italy
[6] Univ Roma La Sapienza, Dipartimento Med Clin, Rome, Italy
[7] Ist Ricovero & Cura & Carattere Sci Demosifilopat, Unita Operat AIDS Rome 71, Rome, Italy
[8] Policlin Bari, Clin Malattie Infett, Bari, Italy
[9] Univ Modena, Clin Malattie Infett & Trop, I-41100 Modena, Italy
[10] Spedali Civil Brescia, Clin Malattie Infett & Trop, I-25125 Brescia, Italy
[11] Osped G Mazzini, Unita Operat Malattie Infett, Teramo, Italy
[12] Osped Macerata, Reparto Malattie Infett, Macerata, Italy
[13] Virol Educ, Utrecht, Netherlands
[14] Virco, Mechelen, Belgium
关键词
D O I
10.1086/503568
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. There is still considerable uncertainty as to the best algorithm for interpreting humanimmunodeficiency virus (HIV) genotyping results. Methods. A total of 318 subjects with HIV RNA levels of > 1000 copies/mL were enrolled in 41 centers throughout Italy from 2001 through 2003, stratified on the basis of their drug history, randomized (1:1) to 2 arms to have their treatments modified on the basis of the results of HIV genotyping (as interpreted by virtual phenotype analysis or with use of a rule-based interpretation system), and followed up for 48 weeks. At least 1 nucleoside reverse-transcriptase inhibitor and 1 protease inhibitor had to be included in any new regimen; nonnucleoside reverse-transcriptase inhibitor naive patients were also prescribed a nonnucleoside reverse-transcriptase inhibitor. Only drugs licensed in Italy were allowed. The primary end point was a decrease in HIV RNA level to < 400 copies/mL by week 12 according to on-treatment analysis. Results. The mean (+/- standard deviation) values at baseline were as follows: HIV RNA level, log(10) copies/mL; CD4(+) T lymphocyte count, cells/mu L; reverse-transcriptase mutations,4.8 +/- 2.9; and protease mutationa, mutations, 2.8 +/- 2.5. There were 133 patients (41.8%) who were nonnucleoside reverse-transcriptase inhibitor naive and protease inhibitor experienced, 63 patients (19.8%) who were nonnucleoside reverse- transcriptase inhibitor experienced and protease inhibitor naive, and 122 patients (38.4%) who were 3-class experienced. A total of 192 patients completed 12 weeks of the treatment regimen assigned at baseline; at 12 weeks, 66.3% of patients in the virtual phenotype arm and 71.3% of patients in the rule-based interpretation arm had HIV RNA levels of ! 400 copies/ mL (P = .46). No statistically significant difference between arms was observed by intention-to-treat analysis. Conclusion. Both the virtual phenotype and rule-based interpretation methods of HIV genotyping can guide the selection of effective antiretroviral drugs for a salvage regimen.
引用
收藏
页码:1470 / 1480
页数:11
相关论文
共 13 条
[1]   A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy [J].
Baxter, JD ;
Mayers, DL ;
Wentworth, DN ;
Neaton, JD ;
Hoover, ML ;
Winters, MA ;
Mannheimer, SB ;
Thompson, MA ;
Abrams, DI ;
Brizz, BJ ;
Ioannidis, JPA ;
Merigan, TC .
AIDS, 2000, 14 (09) :F83-F93
[2]   Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA) [J].
Cingolani, A ;
Antinori, A ;
Rizzo, MG ;
Murri, R ;
Ammassari, A ;
Baldini, F ;
Di Giambenedetto, S ;
Cauda, R ;
De Luca, A .
AIDS, 2002, 16 (03) :369-379
[3]   A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy [J].
Cohen, CJ ;
Hunt, S ;
Sension, M ;
Farthing, C ;
Conant, M ;
Jacobson, S ;
Nadler, J ;
Verbiest, W ;
Hertogs, K ;
Ames, M ;
Rinehart, AR ;
Graham, NM .
AIDS, 2002, 16 (04) :579-588
[4]   Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type I drug resistance [J].
De Luca, A ;
Cingolani, A ;
Di Giambenedetto, S ;
Trotta, MP ;
Baldini, F ;
Rizzo, MG ;
Bertoli, A ;
Liuzzi, G ;
Narciso, P ;
Murri, R ;
Antmassari, A ;
Perno, CF ;
Antinori, A .
JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (12) :1934-1943
[5]   Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial [J].
Durant, J ;
Clevenbergh, P ;
Halfon, P ;
Delgiudice, P ;
Porsin, S ;
Simonet, P ;
Montagne, N ;
Boucher, CAB ;
Schapiro, JM ;
Dellamonica, P .
LANCET, 1999, 353 (9171) :2195-2199
[6]   World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing [J].
Harrigan, PR ;
Montaner, JSG ;
Wegner, SA ;
Verbiest, W ;
Miller, V ;
Wood, R ;
Larder, BA .
AIDS, 2001, 15 (13) :1671-1677
[7]  
Haubrich RH, 2005, AIDS, V19, P295
[8]   Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure:: a randomized trial [J].
Meynard, JL ;
Vray, M ;
Morand-Joubert, L ;
Race, E ;
Descamps, D ;
Peytavin, G ;
Matheron, S ;
Lamotte, C ;
Guiramand, S ;
Costagliola, D ;
Brun-Vézinet, F ;
Clavel, F ;
Girard, PM .
AIDS, 2002, 16 (05) :727-736
[9]   Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients [J].
Monforte, AD ;
Lepri, AC ;
Rezza, G ;
Pezzotti, P ;
Antinori, A ;
Phillips, AN ;
Angarano, G ;
Colangeli, V ;
De Luca, A ;
Ippolito, G ;
Caggese, L ;
Soscia, F ;
Filice, G ;
Gritti, F ;
Narciso, P ;
Tirelli, U ;
Moroni, M .
AIDS, 2000, 14 (05) :499-507
[10]   Limited benefit of antiretrovial resistance testing in treatment-experienced patients: a meta-analysis [J].
Panidou, ET ;
Trikalinos, TA ;
Ioannidis, JPA .
AIDS, 2004, 18 (16) :2153-2161